Pharmafile Logo
Pharmafocus logo
Advanced Search
rd_hands

Japan’s Ono Pharma focusing on building immuno-oncology portfolio with Opdivo

March 7, 2016
Sales and Marketing Bristol-Myers Sqibb, Ono Pharma, immuno-oncology, opdivo

Japan’s Ono Pharmaceutical has said it is focused on building on its immuno-oncology portfolio following the success of its PD-1 …

News
novo_nordisk

Novo Nordisk reports five-year Victoza cardiovascular safety data

March 7, 2016
Research and Development, Sales and Marketing Novo Nordisk, Victoza

Novo Nordisk has announced the top-line results from a trial investigating the cardiovascular safety of Victoza (liraglutide [rDNA origin] injection) …

News
csl_behring

FDA approves CSL Behring’s new haemophilia B treatment

March 7, 2016
Research and Development, Sales and Marketing CSL Behring, haemophilia

The US Food and Drug Administration (FDA) has approved CSL Behring’s Idelvion (Coagulation Factor IX (Recombinant)), a novel, long-acting albumin …

News

Novartis says its psoriasis drug bests Janssen’s in comparison study

March 7, 2016
Research and Development, Sales and Marketing Cosentyx, Novartis, Stelara

Novartis has announced new data from a study comparing its drug Cosentyx to Janssen’s Stelara, which it says demonstrates Cosentyx’s …

News
teva_copy

Teva suffers EpiPen generic setback after FDA rejection

March 4, 2016
Medical Communications, Research and Development FDA, Teva, analphylaxis, approval, auto injector, auto-injector, rejection

The release of Teva Pharmaceuticals generic for the anaphylaxis treatment, EpiPen (epinephrine), is now expected to be severely delayed after …

News
rd_hands

BioMarin reports positive early-stage results for trial drug to treat CLN2 disease

March 4, 2016
Medical Communications

Biotechnology firm BioMarin Pharmaceutical has announced positive results from early stage trial for drug to treat neurodegenerative disease in children.  …

News
merck_logo_blue_rgb

Merck & Pfizer tie-up with Verastem to develop ovarian cancer drug

March 4, 2016
Medical Communications

German drug major Merck along with Pfizer has joined forces with Verastem to develop the trial drug candidate avelumab to …

News
sanofi_logo_vertical_2011_4colors

Sanofi Genzyme present positive Phase 2 results for fatal neuromuscular disease treatment

March 4, 2016
Medical Communications, Research and Development Pompe disease, Sanofi, clinical trial, neuromuscular, phase 2

Sanofi Genzyme, the branch of the French-based pharma company that focuses on diseases difficult to diagnose and treat, have published …

News
magic_bullets_pills

Almost half of US physicians will prescribe more biosimilars, according to survey

March 4, 2016
Medical Communications Obama, US, biosimilar, patent, prescribing

New data published by InCrowd has suggested that US physicians are very amenable to the prescription of biosimilars, with some …

News
baxalta

Baxalta seeks European marketing rights for haemophilia drug

March 3, 2016
Research and Development, Sales and Marketing Adynovi haemophilia a, Baxalta

Baxalta says it has filed for marketing authorisation for its haemophilia drug Adynovi with European regulators. The European Medicines Agency …

News
ucb_logo_and_chief_executive

UCB targets regulatory filing for its osteoporosis drug in 2016

March 3, 2016
Medical Communications, Research and Development, Sales and Marketing Romosozumab, UCB Pharma, osteoporosis

Belgian drug company UCB says it is looking at a regulatory filing for its trial drug romosozumab to treat osteoporosis …

News
the_european_molecular_biology_laboratory

Merck announces drug discovery collaboration with European Molecular Biology Laboratory

March 3, 2016
Research and Development Cancer, Merck, biomarkers

Merck has announced that it has entered into a research collaboration with the European Molecular Biology Laboratory (EMBL), that will …

News
amgen_flag

Amgen sues Novartis over Enbrel biosimilar

March 3, 2016
Research and Development, Sales and Marketing Amgen, Novartis, Sandoz, biosimilars

Amgen has filed a suit in a US court against Novartis’ generics unit Sandoz, in a bid to protect bestselling …

News
deb_jorn

Valeant company group chairman and executive vice president resigns

March 3, 2016
Medical Communications, Sales and Marketing Valeant, appointed, resignation

In an already troubled week for Valeant Pharmaceuticals, the company has now announced that its group chairman and executive vice …

Appointment
gardasil_9

CHMP recommends Sanofi’s two-dose schedule HPV vaccine

March 3, 2016
Research and Development HPV vaccine, MSD, Sanofi Pasteur

Sanofi Pasteur’s and MSD’s vaccine against human papillomavirus (HPV), Gardasil 9, has received a positive opinion from the European Medicine …

News
novo_nordisk

Novo says diabetes drug Xultophy cost-effective versus insulin intensification treatment

March 2, 2016
Sales and Marketing Novo Nordisk, Xultophy, diabetes

Novo Nordisk says findings show its Tresiba and Victoza combo Xultophy (insulin degludec/liraglutide: IDegLira), is cost-effective compared to insulin intensification …

News
nda_group_appointment

Bill Griffiths joins NDA group as general manager UK

March 2, 2016
Medical Communications NDA Group

Industry veteran Bill Griffiths has joined NDA Group to head up the company’s UK consulting team and NDA’s advisory board.  …

Appointment
gilead-sciences

FDA approves Gilead’s Odefsey for treatment of HIV-1 infection

March 2, 2016
Research and Development, Sales and Marketing Gilead Sciences, HIV, Odefsey

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has approved its TAF-based single tablet regimen Odefsey …

News
janssen_latest_logo_on_sign

Janssen slams NICE decision on Imbruvica

March 2, 2016
Research and Development, Sales and Marketing CLL, Cancer, Cancer Drugs Fund, Janssen, Johnson & Johnson, NICE, imbruvica

Janssen, the R&D arm of pharma major Johnson & Johnson, says it is extremely disappointed following regulator NICE’s announcement that …

News
humira_abbott_

Top 10 medicines issued in England by prescription cost in 2014-15

March 2, 2016
Research and Development, Sales and Marketing Cost, Humira, NHS, prescription

AbbVie, Humira (adalimumab), £371m. This drug treats a variety of conditions including psoriatic arthritics, Crohn’s disease and ulcerative colitis. The …

Feature
The Gateway to Local Adoption Series

Latest content

Campaign highlights low expectations among patients with depression

May 7, 2026

Practical AI toolkit launched to help manufacturers cut through complexity

May 6, 2026

Syngene appoints Maninder Kapoor Puri as CHRO

May 6, 2026

BioPhorum acquires PharmaX Solutions

May 5, 2026

Syngene appoints Abhijit Zutshi as CCO

May 5, 2026